May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Visual Acuity and Optical Coherence Tomographic Outcomes Following Intravitreal Triamcinolone Acetonide Injection for Macular Edema Associated with Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • I.U. Scott
    Ophthalmology, Bascom Palmer Eye Inst U Miami, Miami, FL
  • V. Cruz–Villegas
    Ophthalmology, Bascom Palmer Eye Inst U Miami, Miami, FL
  • H.W. Flynn Jr
    Ophthalmology, Bascom Palmer Eye Inst U Miami, Miami, FL
  • C.A. Puliafito
    Ophthalmology, Bascom Palmer Eye Inst U Miami, Miami, FL
  • Footnotes
    Commercial Relationships  I.U. Scott, None; V. Cruz–Villegas, None; H.W. Flynn Jr, None; C.A. Puliafito, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1922. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I.U. Scott, V. Cruz–Villegas, H.W. Flynn Jr, C.A. Puliafito; Visual Acuity and Optical Coherence Tomographic Outcomes Following Intravitreal Triamcinolone Acetonide Injection for Macular Edema Associated with Branch Retinal Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1922.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate visual acuity and optical coherence tomographic outcomes, and adverse events, associated with intravitreal triamcinolone acetonide injection(s) for macular edema secondary to branch retinal vein occlusion (BRVO). Methods: Retrospective, non–comparative, interventional, consecutive case series. Records were reviewed of all patients treated for macular edema secondary to BRVO with intravitreal injection(s) of triamcinolone acetonide (4mg/0.1cc) by 1 of 3 vitreoretinal surgeons between January 2001 and April 2003. Results: The study included 19 eyes of 19 patients with a median follow–up of 6 months. Median visual acuity was 20/300 pre–treatment (n=19) compared to 20/70 at 1 month (p=.001; n=17); 20/60 at 3 months (p=.003; n=13); 20/60 at 6 months (p=.012; n=10); and 20/135 (p=.66; n=4) at 1 year. Acuity improved by halving of the visual angle in 12/17 eyes at 1 month, 9/13 at 3 months, 6/10 at 6 months, and 1/4 at 1 year. Mean foveal thickness was 465µm at baseline, compared to 267µm at 1 month (p<.001); 261µm at 3 months (p<.001); 321µm at 6 months (p=.002); and 340µm (p=.31) at 1 year. The probability of a second injection was 52% by 6 months and 68% by 1 year. An intraocular pressure (IOP) elevation >10 mmHg compared to pre–injection occurred in 2/17 patients at 1 month, 3/13 at 3 months, 0/10 at 6 months, and 0/4 at 1 year. Elevated IOP was controlled with medications in all cases. Conclusions: Intravitreal triamcinolone was associated with improved visual acuity and decreased macular edema in most patients; these changes may be transient.

Keywords: vascular occlusion/vascular occlusive disease • retina • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×